MAPT and Alzheimer disease: Statistically, the incidence of AD has increased in people with type 2 diabetes, and a series of studies have found that hypoglycemic drugs, including rosiglitazone, pioglitazone, and liraglutide, can reduce the deposition of Aβ or tau proteins in the body, thereby improving cognitive performance in patients [79,80,81,82,83].